Menu
Search
|

Menu

Close
X

Steadymed Ltd STDY.OQ (NASDAQ Stock Exchange Global Market)

3.05 USD
+0.00 (+0.00%)
As of 2:29 AM IST
chart
Previous Close 3.05
Open 3.05
Volume 2
3m Avg Volume 11,590
Today’s High 3.05
Today’s Low 3.05
52 Week High 9.65
52 Week Low 2.85
Shares Outstanding (mil) 26.56
Market Capitalization (mil) 84.98
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
1
FY15
1
EPS (USD)
FY17
-0.923
FY16
-1.676
FY15
-1.884
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
69.09
5.77
Price to Book (MRQ)
vs sector
4.29
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-128.53
14.43
Return on Equity (TTM)
vs sector
-221.79
16.13

EXECUTIVE LEADERSHIP

Keith Bank
Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Jonathan Rigby
President, Chief Executive Officer, Director, Since 2014
Salary: $431,200.00
Bonus: --
David Nassif
Chief Financial Officer, Executive Vice President, Since 2015
Salary: $351,750.00
Bonus: --
Elizabeth Cermak
Independent Director, Since 2015
Salary: --
Bonus: --
Stephen Farr
Independent Director, Since 2012
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5 Oppenheimer Street
REHOVOT     7670105

Phone: +9723.6449556

SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company's ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting.

SPONSORED STORIES